Single and dual quarter-dose blood pressure therapies showed significant efficacy (P<0.001) with significantly fewer adverse events than standard-dose monotherapy and similar safety to placebo.
Absolute Event Rate: 0% vs 0%
<0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Alexander Bennett
The University of Sydney
Clara K Chow
Preventive Cardiology
Michael F. Chou
Institute of Neuroimmunology of the Slovak Academy of Sciences
Hypertension
Johns Hopkins University
University College London
Imperial College London
Building similarity graph...
Analyzing shared references across papers
Loading...
Bennett et al. (Tue,) reported a other. Single and dual quarter-dose blood pressure therapies showed significant efficacy (P<0.001) with significantly fewer adverse events than standard-dose monotherapy and similar safety to placebo.
synapsesocial.com/papers/6a07b56015d371b388386a8c — DOI: https://doi.org/10.1161/hypertensionaha.117.09202
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: